Differences
This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionBoth sides next revision |
pharmaceutical_companies:rising_pharmaceuticals [2023/05/16 20:01] liam | pharmaceutical_companies:rising_pharmaceuticals [2024/11/17 20:03] (current) liam [External links] |
---|
==== COVID-19 ==== | ==== COVID-19 ==== |
| |
On March 20, 2020, Rising Pharmaceuticals announced it would be lowering prices on the [[:hydroxychloroquine]] it manufactured as well as donating 1 million doses "between March and April to areas of greatest need through participating distributors and government agencies."((Perez, K. (2020, March 20). //Rising Pharmaceuticals Responds to Pandemic by Lowering Prices and Donating Product.// Business Wire. http://archive.today/2023.05.16-163513/https://www.businesswire.com/news/home/20200320005458/en/Rising-Pharmaceuticals-Responds-Pandemic-Lowering-Prices-Donating)) The company also donated doses of the drug for use in the first [[randomized control trial]] (RCT) evaluating use of HCQ in treating [[COVID-19]], led by [[David Boulware]].((Boulware, D. (2020). //ICMJE Form for Disclosure of Potential Conflicts of Interest.// In New England Journal of Medicine (pp. 8–9). https://web.archive.org/web/20230516161717/https://www.nejm.org/doi/suppl/10.1056/NEJMoa2016638/suppl_file/nejmoa2016638_disclosures.pdf)) | On March 20, 2020, Rising Pharmaceuticals announced it would be lowering prices on the [[:hydroxychloroquine]] it manufactured as well as donating 1 million doses "between March and April to areas of greatest need through participating distributors and government agencies."((Perez, K. (2020, March 20). //Rising Pharmaceuticals Responds to Pandemic by Lowering Prices and Donating Product.// Business Wire. http://archive.today/2023.05.16-163513/https://www.businesswire.com/news/home/20200320005458/en/Rising-Pharmaceuticals-Responds-Pandemic-Lowering-Prices-Donating)) The company also donated doses of the drug for use in the first [[:randomized control trial]] (RCT) evaluating use of HCQ in treating [[:COVID-19]], led by [[:David Boulware]].((Boulware, D. (2020). //ICMJE Form for Disclosure of Potential Conflicts of Interest.// New England Journal of Medicine (pp. 8–9). https://web.archive.org/web/20230516161717/https://www.nejm.org/doi/suppl/10.1056/NEJMoa2016638/suppl_file/nejmoa2016638_disclosures.pdf)) |
| |
===== External links ===== | ===== External links ===== |
| |
| * [[http://covidtruthinitiative.ca/en/Organizations/Rising-Pharmaceuticals|COVID Truth Initiative]] |
* [[https://risingpharma.com/|Website]] | * [[https://risingpharma.com/|Website]] |
| * [[https://wiki.whiteroseintelligence.com/en/Rising-Pharmaceuticals|White Rose Wiki]] |